Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PMDA Cuts Review Lag With West In Half, But Application Lag Shows No Relief For Drug Launches In Japan

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Japan's Pharmaceuticals and Medical Devices Agency has reduced its drug review lag in half since rolling out a plan two years ago to cut the drug lag, but products launched in the U.S. still hold a two-year head start compared to products launches in Japan, according to new estimates released by Japan's drug regulatory agency

You may also be interested in...



Japan's MHLW Approves Request For Needed Drugs That Can Bypass Clinical Trials

TOKYO - Japan's Ministry of Health, Labor and Welfare is urging manufacturers to develop drugs for Japan that are still unapproved or unapproved for additional indications already approved in the West. Some drugs considered highly medically necessary may qualify for approval via a known-art application without conducting new clinical trials in Japan. The move is part of the ministry's ongoing efforts to reduce the country's much talked about drug lag

Japan's MHLW Approves Request For Needed Drugs That Can Bypass Clinical Trials

TOKYO - Japan's Ministry of Health, Labor and Welfare is urging manufacturers to develop drugs for Japan that are still unapproved or unapproved for additional indications already approved in the West. Some drugs considered highly medically necessary may qualify for approval via a known-art application without conducting new clinical trials in Japan. The move is part of the ministry's ongoing efforts to reduce the country's much talked about drug lag

Asia Raises Bar for New Drugs, Manufacturers With Tougher CMC Reviews, GMP Inspections: A Look At Japan (Part 5)

The one Asian country with "first-tier" status, Japan may be on a par with the U.S. and the EU in the International Conference on Harmonization, but the country nevertheless faces challenges in the CMC and GMP arenas, said Pramod Kotwal of Merck, Sharpe and Dohme

Related Content

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel